Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YH18968
- Development stage
- Preclinical
- Lead developer
- Yuhan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YH18968 is a novel small molecule agonist of G-protein coupled receptor 119 (GPR119), developed for the treatment of type 2 diabetes mellitus. It belongs to the chemical class of 1,2,4-triazolones. The drug acts by activating GPR119, which leads to increased secretion of glucagon-like peptide-1 (GLP-1) from intestinal L cells and enhances glucose-stimulated insulin secretion (GSIS). This dual action improves glucose tolerance and augments the plasma level of active GLP-1, thereby contributing to better glycemic control in diabetic models[1][3][5]. Preclinical studies have demonstrated its efficacy in improving glucose homeostasis.
02
Targets
GPR119 (Glucose-dependent insulinotropic receptor)
Beyond the preview
Go deeper on YH18968.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YH18968.